[Analysis of the results of treatment of multiple myeloma]

Therapeutic results were analysed in 62 cases of multiple myeloma treated by two-stage method: I. with cyclically non-specific agents (melphalan) in each case. When this treatment was a failure the second step was given: II. cyclically specific and non-specific agents by the M-2 schedule. Good therapeutic response was obtained in 70% of cases. The mean survival time in the whole group was 35 months, and in the subgroup with good prognosis it was 44 months. Most (74%) patients with IgG M-protein responded well to treatment with cyclically non-specific agents, while only 50% of those with IgA M-protein had a good response to them.